Swedish online pharmacy Meds has reported growth in both turnover and adjusted operating result for the second quarter of 2026.
The company posted an adjusted EBITDA of SEK 60 million for the three-month period, an increase from SEK 43 million in the corresponding quarter of 2025.
The results indicate continued expansion in the digital pharmacy segment.
Meds operates as a key player in the Swedish e-pharmacy market, competing for market share in a sector characterized by high growth potential and regulatory scrutiny.
The improvement in profitability metrics suggests the company is successfully scaling its operations.
Investors will be looking for further details on the revenue drivers behind the growth, including prescription volume and customer acquisition costs, when the full financial report is released.